Michael Bian

Mr. Michael Bian

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
MBMichael Bian
Michael Bian
GNGeorge Nassief
George Nassief
VRVictoria Hope Ruesch
Victoria Hope Ruesch
VGViraj Gorthi
Viraj Gorthi
FCFumiko Chino
Fumiko Chino
LRLuke D. Rothermel
Luke D. Rothermel
PURPOSE: The 2021 Federal Hospital Price Transparency Final Rule requires hospitals to publicly disclose payer-negotiated prices for services. Despite rising cutaneous melanoma incidence and strong association with geographic ultraviolet light exposure, price transparency for melanoma-specific care is incompletely understood. We assessed regional price compliance and variation among National Cancer Institute–designated Comprehensive Cancer Centers (NCI-CCCs) to inform clinician-patient cost discussions. METHODS: A cross-sectional analysis was conducted of private payer-specific negotiated prices in 2025 for 53 melanoma-related procedures using publicly available hospital price transparency files. Fifty-eight NCI-CCCs providing adult clinical care were included (data extracted January 1-March 31, 2025). Primary outcomes were markups relative to Medicare reimbursement and price dispersion across and within centers by billing code. Secondary outcomes included compliance with price transparency, markups, and price dispersion by US Census division. RESULTS: Overall, 47/58 centers (81.0%) were federally compliant, with lymph node procedures showing the highest median (IQR) markups relative to Medicare 7.9 (5.5-9.5). Diagnostic testing/imaging demonstrated the greatest price dispersion, with median (IQR) across-center and within-center ratios of 13.4 (9.5-16.6) and 11.2 (9.6-12.7), respectively. The Pacific division had the highest median price markups at 8.9 (3.7-13.4) and included five noncompliant centers. Across divisions, within- and across-center price dispersion were strongly correlated (ρ = 0.88; 95% CI, 0.53 to 1.00). CONCLUSION: The use of lymph node procedures, diagnostic testing, and imaging presents a key opportunity to mitigate financial toxicity for at-risk patients. Improved clinical accessibility of pricing data and policy intervention is still needed to advance patient-centered, value-driven care.

7 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
MBMichael Bian
Michael Bian
RSReagan Stevens
Reagan Stevens
Ankit ManglaAnkit Mangla
Ankit Mangla
DMDevarati Mitra
Devarati Mitra
NZNicholas G. Zaorsky
Nicholas G. Zaorsky
LRLuke D. Rothermel
Luke D. Rothermel
Background/Objectives: Immune checkpoint inhibitors (ICIs) and other systemic therapies can extend the survival of many patients with advanced melanoma, renewing interest in complementary strategies for unresectable or metastatic disease. Therapeutic cancer vaccines represent a possible approach. Recent evidence suggests commercially available mRNA vaccines can sensitize tumors to ICIs, challenging prior assumptions about neoantigen presentation. Despite renewed public interest in personalized cancer vaccine development, the proliferation of narrative and scoping reviews has not been matched by systematic mechanistic synthesis—platforms investigated across the 2010s and 2020s have not been rigorously compared within a single article. Accordingly, this review focuses on major vaccine platforms and proposes a comparative framework for understanding therapeutic melanoma vaccine development and immunologic rationale. Methods: Melanoma vaccine clinical trials listed on ClinicalTrials.gov were identified from 2010 to 2025. Eligible studies were screened and included in a qualitative review evaluating trial characteristics, vaccine platforms, study design, and reported outcomes. Results: There is one active Phase III clinical trial for melanoma vaccines in the US. Key principles of melanoma vaccinology include adjuvant, antigen, and delivery platform selection. From 2010 to 2025, four vaccine candidates advanced to Phase III trials, two provided Phase III results for peer review, one trial is ongoing, and no vaccines have been FDA-approved. Inconsistent reporting of outcomes and a lack of published results limited comparability across studies, precluding formal meta-analysis. Conclusions: Therapeutic melanoma vaccine options remain limited by translational challenges in study design and reporting gaps. This review synthesizes contemporary clinical trial activity and immunologic principles to inform future research.